BRAF and melanoma: This metabolic phenotype, which is present irrespective of the expression of PGC1α, renders BRAF inhibitor–resistant melanoma cells highly vulnerable to several mitochondrial-targeted compounds including the mitochondrial pro-oxidative drug, elesclomol.